These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21997619)

  • 1. Drug pipeline: Q311.
    Peng W
    Nat Biotechnol; 2011 Oct; 29(10):859. PubMed ID: 21997619
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug pipeline 4Q13.
    DeFrancesco L
    Nat Biotechnol; 2014 Feb; 32(2):125. PubMed ID: 24509748
    [No Abstract]   [Full Text] [Related]  

  • 3. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 4. Paediatric clinical trials: redressing the imbalance.
    Schreiner MS
    Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
    [No Abstract]   [Full Text] [Related]  

  • 5. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 6. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 7. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 8. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 10. The seduction of biomarkers in the practice of medicine and the tyranny of power in the drug approval process: lessons from niacin.
    Lehmann DF; Sitar DS
    J Clin Pharmacol; 2011 Nov; 51(11):1496-8. PubMed ID: 21998350
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the drought over for pharming?
    Kaiser J
    Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
    [No Abstract]   [Full Text] [Related]  

  • 12. Pediatric drug studies. Protecting pint-sized patients.
    Nordenberg T
    FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
    [No Abstract]   [Full Text] [Related]  

  • 13. From proposal to patient: how CMS makes coverage decisions.
    Turnbull GB
    Ostomy Wound Manage; 2002 Apr; 48(4):8-10, 82. PubMed ID: 11993063
    [No Abstract]   [Full Text] [Related]  

  • 14. US court rules to allow experimental drugs for dying patients.
    Waltz E
    Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 16. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 17. What's in the pipeline.
    Glazer WM
    Behav Healthc; 2007 Dec; 27(12):19-21. PubMed ID: 18429587
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug pipeline: Q310.
    Peng W
    Nat Biotechnol; 2010 Oct; 28(10):998. PubMed ID: 20944578
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethical implications of pediatric drug research policy initiatives.
    Twomey JG
    IRB; 2000; 22(2):5-10. PubMed ID: 11883466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.